Skip to main content

Table 1 Trends of malaria intervention coverage indicators, Mali, 2000–2015

From: Impact evaluation of malaria control interventions on morbidity and all-cause child mortality in Mali, 2000–2012

Interventions

2001

% (95% CI)

N

2006

% (95% CI)

N

2010

% (95% CI)

N

2012–2013

 % (95% CI)

N

2015

% (95% CI)

N

Changea

p£

Nets

 Household ownership

n/a

40.5 (37.3–42.7)

31,910

62.9 (60.3–65.4)

7883

70.6 (69.4–71.8)

47,829

n/a

30.1

< 0.0001

ITNs

 Household ownership ≥1

n/a

49.4 (46.6–52.2)

11,109

87.2 (84.1–89.7)

1428

84.4 (83.1–85.6)

10,105

93.0 (91.8–94.1)

4240

43.6

< 0.0001

 Use (children < 5 yrs)

n/a

26.4 (24.0–29.0)

11,640

72.6 (68.2–76.7)

1801

69.0 (67.2–70.7)

10,634

71.2 (68.9–69.6)

7880

44.8

< 0.0001

 Use (pregnant women)

n/a

27.6 (23.4–32.2)

1677

 

73.2 (69.6–76.5)

1200

77.9 (74.4–81.0)

774

50.3

< 0.0001

 Use (all persons)

n/a

20.7 (18.9–22.5)

61,758

56.9 (53.8–59.9)

8721

60.5 (59.0–62.0)

55,836

63.9 (62.0–65.8)

37,755

43.2

< 0.001

IPTp during last pregnancy

 2+ doses

n/a

10.1 (8.6–12.0)

4989

NA

28.5 (26.3–30.9)

3965

37.8 (34.5–41.1)

3017

27.7

< 0.0001

Recommended first-line malaria treatment

 

92.4* (90.0–94.3) 1049

5.5b (3.6–8.3)

677

23.3c (15.8–32.9)

241

19.0c (13.4–26.3)

187

28.9c (23.0–35.8)

590

5.6

0.0171

  1. * Chloroquine used as first-line therapy in 2001
  2. £ P value of Chi squared for the two time points indicating the changes above
  3. aAbsolute change from 2006 to 2015, except for recommended first-line malaria treatment where 2010 was the starting point
  4. bSulfadoxine-pyrimethamine used in 2006
  5. cArtemisinin combination therapy used in 2010, 2012–2013, and 2015